GSK plc

GLAXFOTCHealthcare● Active

$23.54

$-0.40(-1.67%)

Market Cap$94.4B

P/E Ratio—

52W High$31.48

52W Low$17.15

Avg Volume849

Open$23.54

Beta0.29

Overview

GSK plc (GLAXF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

glaxf · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for GSK plc (GLAXF) measures how much investors pay for each dollar of the company's trailing earnings. GLAXF's current PE ratio of 13.20x is calculated by dividing its stock price of $23.54 by its TTM earnings per share of $1.45. +1.6% elevated vs 5Y avg 13.0x

13.20x

P/E Ratio (TTM)+1.6%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E

8.93x

FY2027 est. EPS $2.64

Based on 6 analysts

EPS (TTM)

$1.45

TTM · diluted EPS

PEG Ratio

0.15

Below 1.0 · Growth adjusted

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GSK plc SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual

PE Ratio (TTM)

5Y Avg 13.0x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 20 fiscal years · Front-end computed

Average

20.3x

20-yr mean

Median

14.1x

20-yr midpoint

Minimum

3.9x

Lowest year

Maximum

83.6x

Highest year

13.2x ← Now

3.9x
MinQ1 · 25%14.1x
MedianQ3 · 75%83.6x
Max

Within Historical Range

At 13.20x, GLAXF's current P/E is within its average historical range over the past 20 fiscal years.

30th percentileHigher than 6 of 20 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Drug Manufacturers - General · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
GSK plcYou GLAXF	$94.4B	13.20x	-54.5%	$1.45
Chugai Pharmaceutical Co., Ltd. CHGCF	$77.2B	32.63x	+12.4%	$263.96
Chugai Pharmaceutical Co., Ltd. CHGCY	$77.4B	29.80x	+2.6%	$138.26
CSL Limited CSLLY	$66.2B	51.08x	+75.9%	$0.78
Daiichi Sankyo Company, Limited DSKYF	$29.5B	20.69x	-28.8%	$141.33
Daiichi Sankyo Company, Limited DSNKY	$29.2B	19.10x	-34.2%	$148.91
Merck KGaA MKGAF	$67.4B	20.95x	-27.9%	$6.00
Industry Average 6 peers with valid PE	—	29.04x	baseline	—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2025-12-31Latest FY2025	12.94x	$1.41	-39.3%
2024-12-31 FY2024	21.31x	$0.63	+76.1%
2023-12-31 FY2023	12.10x	$1.20	+210.9%
2022-12-31 FY2022	3.89x	$3.71	-73.7%
2021-12-31 FY2021	14.77x	$1.37	+31.1%
2020-12-31 FY2020	11.27x	$1.44	-40.6%
2019-12-31 FY2019	18.97x	$1.17	-4.8%
2018-12-31 FY2018	19.94x	$0.92	-52.0%
2017-12-31 FY2017	41.55x	$0.39	-50.3%
2016-12-31 FY2016	83.57x	$0.23	+927.0%

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $23.54 ÷ $1.45 = 13.20x

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

GLAXF pe ratio · 6 questions

GLAXF's current PE ratio is 13.20x as of 2026-06-08, based on a stock price of $23.54 and TTM EPS of $1.45. Data sourced from Financial Modeling Prep via GLAXF's SEC 10-K and 10-Q filings.

GLAXF PE ratioWhat is GLAXF PE ratioCurrent PE ratio of GLAXFGLAXF PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GSK plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08